488
Views
8
CrossRef citations to date
0
Altmetric
Original Articles

Characterization of a G1P[8] rotavirus causing an outbreak of gastroenteritis in the Northern Territory, Australia, in the vaccine era

, , , , &
Pages 1-6 | Received 23 Sep 2015, Accepted 02 Nov 2015, Published online: 25 Jan 2019

  • Glass RI, Parashar UD, Bresee JS et al.Rotavirus vaccines: current prospects and future challenges. Lancet2006;368: 323–332.
  • Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD.2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis2012;12: 136–141.
  • Estes MK, Kapikian AZ. Fields' virology.5th ed. Vol. 2.Philadelphia, PA: Lippincott Williams & Wilkins, 2007.
  • Matthijnssens J, Otto PH, Ciarlet M, Desselberger U, van Ranst M, Johne R.VP6-sequence-based cutoff values as a criterion for rotavirus species demarcation. Arch Virol2012;157: 1177–1182.
  • Matthijnssens J, Ciarlet M, McDonald SM et al.Uniformity of rotavirus strain nomenclature proposed by the Rotavirus Classification Working Group (RCWG). Arch Virol2011;156: 1397–1413.
  • Guo D, Liu J, Lu Y et al.Full genomic analysis of rabbit rotavirus G3P[14] strain N5 in China: identification of a novel VP6 genotype. Infect Genet Evol2012;12: 1567–1576.
  • Papp H, Al-Mutairi LZ, Chehadeh W et al.Novel NSP4 genotype in a camel G10P[15] rotavirus strain. Acta Microbiol Immunol Hung2012;59: 411–421.
  • Trojnar E, Sachsenroder J, Twardziok S, Reetz J, Otto PH, Johne R.Identification of an avian group A rotavirus containing a novel VP4 gene with a close relationship to those of mammalian rotaviruses. J Gen Virol2013;94: 136–142.
  • Jere KC, Esona MD, Ali YH et al.Novel NSP1 genotype characterised in an African camel G8P[11] rotavirus strain. Infect Genet Evol2014;21: 58–66.
  • Dennehy PH.Effects of vaccine on rotavirus disease in the pediatric population. Curr Opin Pediatr2012;24: 76–84.
  • Vesikari T, Matson DO, Dennehy P et al.Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med2006;354: 23–33.
  • Ruiz-Palacios GM, Perez-Schael I, Velazquez FR et al.Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med2006;354: 11–22.
  • Patel M, Pedreira C, de Oliveira LH et al.Duration of protection of pentavalent rotavirus vaccination in Nicaragua. Pediatrics2012;130: e365–e372.
  • Paulke-Korinek M, Kundi M, Rendi-Wagner P et al.Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine2011;29: 2791–2796.
  • Hanquet G, Ducoffre G, Vergison A et al.Impact of rotavirus vaccination on laboratory confirmed cases in Belgium. Vaccine2011;29: 4698–4703.
  • Ichihara MY, Rodrigues LC, Teles Santos CA et al.Effectiveness of rotavirus vaccine against hospitalized rotavirus diarrhea: a case–control study. Vaccine2014;32: 2740–2747.
  • Quintanar-Solares M, Yen C, Richardson V, Esparza-Aguilar M, Parashar UD, Patel MM.Impact of rotavirus vaccination on diarrhea-related hospitalizations among children <5 years of age in Mexico. Pediatr Infect Dis J2011;30(1 Suppl): S11–S15.
  • Vesikari T, Karvonen A, Prymula R et al.Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet2007;370: 1757–1763.
  • Heaton PM, Goveia MG, Miller JM.Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis. J Infect Dis2005;192( Suppl 1): S17–S21.
  • Buttery JP, Lambert SB, Grimwood K et al.Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule. Pediatr Infect Dis J2011;30 (1 Suppl): S25–29.
  • Snelling T, Markey P, Carapetis J, Andrews R.Rotavirus in the Northern Territory before and after vaccination. Microbiol Aust2012;33: 61–63.
  • Macartney KK, Porwal M, Dalton D et al.Decline in rotavirus hospitalisations following introduction of Australia's national rotavirus immunisation programme. J Paediatr Child Health2011;47: 266–270.
  • Dyall-Smith ML, Holmes IH.Sequence homology between human and animal rotavirus serotype-specific glycoproteins. Nucleic Acids Res1984;12: 3973–3982.
  • Herring AJ, Inglis NF, Ojeh CK, Snodgrass DR, Menzies JD.Rapid diagnosis of rotavirus infection by direct detection of viral nucleic acid in silver-stained polyacrylamide gels. J Clin Microbiol1982;16: 473–477.
  • Cowley D, Donato CM, Roczo-Farkas S, Kirkwood CD.Novel G10P[14] rotavirus strain, Northern Territory, Australia. Emerg Infect Dis2013;19: 1324–1327.
  • Coulson BS, Fowler KJ, Bishop RF, Cotton RG.Neutralizing monoclonal antibodies to human rotavirus and indications of antigenic drift among strains from neonates. J Virol1985;54: 14–20.
  • Coulson BS, Kirkwood C.Relation of VP7 amino acid sequence to monoclonal antibody neutralization of rotavirus and rotavirus monotype. J Virol1991;65: 5968–5974.
  • Coulson BS.Typing of human rotavirus VP4 by an enzyme immunoassay using monoclonal antibodies. J Clin Microbiol1993;31: 1–8.
  • Kirkwood CD, Bishop RF, Coulson BS.Human rotavirus VP4 contains strain-specific, serotype-specific and cross-reactive neutralization sites. Arch Virol1996;141: 587–600.
  • McDonald SM, Matthijnssens J, McAllen JK et al.Evolutionary dynamics of human rotaviruses: balancing reassortment with preferred genome constellations. PLoS Pathog2009;5: e1000634.
  • Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S.MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol2011;28: 2731–2739.
  • Edgar RC.MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res2004;32: 1792–1797.
  • Darriba D, Taboada GL, Doallo R, Posada D.jModelTest 2: more models, new heuristics and parallel computing. Nat Meth2012;9: 772.
  • Guindon S, Gascuel O.A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol2003;52: 696–704.
  • DeLano WL.Unraveling hot spots in binding interfaces: progress and challenges. Curr Opin Struct Biol2002;12: 14–20.
  • Maes P, Matthijnssens J, Rahman M, van Ranst M.RotaC: a web-based tool for the complete genome classification of group A rotaviruses. BMC Microbiol2009;9: 238.
  • Trask SD, Kim IS, Harrison SC, Dormitzer PR.A rotavirus spike protein conformational intermediate binds lipid bilayers. J Virol2010;84: 1764–1770.
  • Mackow ER, Shaw RD, Matsui SM, Vo PT, Dang MN, Greenberg HB.The rhesus rotavirus gene encoding protein VP3: location of amino acids involved in homologous and heterologous rotavirus neutralization and identification of a putative fusion region. Proc Natl Acad Sci USA1988;85: 645–649.
  • Kirkwood CD, Roczo S, Boniface K, Bishop RF, Barnes GL, Australian Rotavirus Surveillance Group.Australian Rotavirus Surveillance Program annual report, 2010/11. Commun Dis Intell Q Rep2011;35: 281–287.
  • Zeller M, Patton JT, Heylen E et al.Genetic analyses reveal differences in the VP7 and VP4 antigenic epitopes between human rotaviruses circulating in Belgium and rotaviruses in Rotarix and RotaTeq. J Clin Microbiol2012;50: 966–976.
  • Ward RL, Kirkwood CD, Sander DS et al.Reductions in cross-neutralizing antibody responses in infants after attenuation of the human rotavirus vaccine candidate 89-12. J Infect Dis2006;194: 1729–1736.
  • Kobayashi N, Taniguchi K, Urasawa S.Identification of operationally overlapping and independent cross-reactive neutralization regions on human rotavirus VP4. J Gen Virol1990;71: 2615–2623.
  • Desselberger U, Huppertz HI.Immune responses to rotavirus infection and vaccination and associated correlates of protection. J Infect Dis2011;203: 188–195.
  • Snelling TL, Schultz R, Graham J et al.Rotavirus and the indigenous children of the Australian outback: monovalent vaccine effective in a high-burden setting. Clin Infect Dis2009;49: 428–431.
  • Snelling TL, Andrews RM, Kirkwood CD, Culvenor S, Carapetis JR.Case–control evaluation of the effectiveness of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in central Australia. Clin Infect Dis2011;52: 191–199.
  • Hull B, Dey A, Menzies R, McIntyre P.Annual immunisation coverage report, 2010. Commun Dis Intell Q Rep2013;37: E21–E39.
  • Patel M, Glass RI, Jiang B, Santosham M, Lopman B, Parashar U.A systematic review of anti-rotavirus serum IgA antibody titer as a potential correlate of rotavirus vaccine efficacy. J Infect Dis2013;208: 284–294.
  • Madhi SA, Cunliffe NA, Steele D et al.Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med2010;362: 289–298.
  • Gladstone BP, Ramani S, Mukhopadhya I et al.Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med2011;365: 337–346.
  • Li QS, Guthridge S, d'Espaignet ET, Paterson B.From infancy to young adulthood: health status in the Northern Territory, 2006.Darwin: Department of Health and Community Services, 2006.Available at: http://digitallibrary.health.nt.gov.au/dspace/bitstream/10137/84/1/infancy_to_young_adulthood_2006.pdf (accessed 13 June 2013).